Phase 1/2 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HQK-1001 Administered Daily in Patients With Sickle Cell Disease
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Susan Perrine, M.D.
HemaQuest Pharmaceuticals
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
9 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of the West Indies, Mona
Kingston, Mona, Jamaica
- Trialogic Research
Madison, Alabama, United States
- Children'S Hospital and Research Center at Oakland
Oakland, California, United States
- Century Clinical Research, Inc.
Daytona Beach, Florida, United States
- Medical College of Georgia
Augusta, Georgia, United States
- University of Illinois at Chicago
Chicago, Illinois, United States
- Johns Hopkins School of Medicine
Baltimore, Maryland, United States
- Unc Comprehensive Sickle Cell Program
Chapel Hill, North Carolina, United States
- Texas Children'S Cancer Center and Hematology Service
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Mar 2009
- Primary completion
- 31 Jul 2010
- Completion
- —
- Last update posted
- 1 Aug 2011
- Registered enrollment
- 24
- Registry id
- NCT00842088
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.